ABSTRACT
Background The use of PCSK9 inhibitors in the management of cardiovascular disease has gained increasing attention. However, there is limited evidence on their cost-utility and impact on quality of life in real-world settings. This study aimed to conduct a real-world cost-utility analysis of PCSK9 inhibitors and evaluating their effects on quality of life.
Methods A multicenter prospective study was conducted across 12 Spanish hospitals from May 2020 to April 2022, involving 158 patients. QoL was assessed using the EQ-5D questionnaire. Cost-utility analysis assessed the economic impact of PCSK9 inhibitors when used with standard care compared to standard care alone, calculating the incremental cost-effectiveness ratio (ICER).
Results The study encompassed 158 patients with an average age of 61, predominantly male (66.5%). For patients initiating PCSK9 inhibitors, the cost of PCSK9 inhibitor treatment was €13,633.39, while standard therapy cost €3,638.25 over two years. Qualys for PCSK9 inhibitors stood at 1.648851948 over two years, compared to 1.454807792 for standard therapy. The results revealed favorable cost-utility outcomes, with an ICER of €51,427.72. Significant improvements were observed in the domains of mobility, self-care, daily activities, pain/discomfort, and anxiety/depression (p<0.001).
Conclusions This study represents the first real-world cost-utility analyses of PCSK9 inhibitors. The findings support the economic justification and potential benefits of incorporating PCSK9 inhibitors into clinical practice. Healthcare decision-makers can consider these results when making informed decisions and reimbursement regarding the use of PCSK9 inhibitors in clinical practice.
Trial Registration clinicaltrials.gov Identifier: NCT04319081
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
Trial Registration clinicaltrials.gov Identifier: NCT04319081
Funding Statement
Funding The authors declare that no funds, grants, or other support were received during the preparation of this manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics approval This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Servizo Galego de Saúde (Date 29-JAN-2020 /No. 2019/653) and Agencia Española de Medicamentos y Productos Santiarios (Date 28-JAN-2020)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Availability of data and material (data transparency) In this article, we are committed to data transparency and availability of materials used in our research. The data and materials will be available on demand for readers interested in replicating or building upon our study. Interested parties can contact the corresponding author to request access to the data and materials. We will ensure that the requested information and materials are provided in a timely and complete manner.
